[a47def]: / Debernardi et al 2020 documentation.csv

Download this file

# Column name Original column name Details
1 sample_id Sample ID Unique string identifying each subject
2 patient_cohort Patient's Cohort Cohort 1, previously used samples; Cohort 2, newly added samples
3 sample_origin Sample Origin BPTB: Barts Pancreas Tissue Bank, London, UK; ESP: Spanish National Cancer Research Centre, Madrid, Spain; LIV: Liverpool University, UK; UCL: University College London, UK
4 age Age Age in years
5 sex Sex M = male, F = female
6 diagnosis Diagnosis (1=Control, 2=Benign, 3=PDAC) 1 = control (no pancreatic disease), 2 = benign hepatobiliary disease (119 of which are chronic pancreatitis); 3 = Pancreatic ductal adenocarcinoma, i.e. pancreatic cancer
7 stage Stage For those with pancratic cancer, what stage was it? One of IA, IB, IIA, IIIB, III, IV
8 benign_sample_diagnosis Benign Samples Diagnosis For those with a benign, non-cancerous diagnosis, what was the diagnosis?
9 plasma_CA19_9 Plasma CA19-9 U/ml Blood plasma levels of CA 19–9 monoclonal antibody that is often elevated in patients with pancreatic cancer. Only assessed in 350 patients (one goal of the study was to compare various CA 19-9 cutpoints from a blood sample to the model developed using urinary samples).
10 creatinine Creatinine mg/ml Urinary biomarker of kidney function
11 LYVE1 LYVE1 ng/ml Urinary levels of Lymphatic vessel endothelial hyaluronan receptor 1, a protein that may play a role in tumor metastasis
12 REG1B REG1B ng/ml Urinary levels of a protein that may be associated with pancreas regeneration.
13 TFF1 TFF1 ng/ml Urinary levels of Trefoil Factor 1, which may be related to regeneration and repair of the urinary tract
14 REG1A REG1A ng/ml Urinary levels of a protein that may be associated with pancreas regeneration. Only assessed in 306 patients (one goal of the study was to assess REG1B vs REG1A)